Show simple item record

dc.contributor.authorFeng, Panpan
dc.contributor.authorChen, Dawei
dc.contributor.authorWang, Xia
dc.contributor.authorLi, Yanxia
dc.contributor.authorLi, Zhenyu
dc.contributor.authorLi, Boya
dc.contributor.authorZhang, Yupeng
dc.contributor.authorLi, Wei
dc.contributor.authorZhang, Jingru
dc.contributor.authorYe, Jingjing
dc.contributor.authorZhao, Baobing
dc.contributor.authorLi, Jingxin
dc.contributor.authorJi, Chunyan
dc.date.accessioned2022-11-04T18:56:00Z
dc.date.available2022-11-04T18:56:00Z
dc.date.created2022-09-30T09:56:01Z
dc.date.issued2022-08-01
dc.identifier.citationLeukemia. 2022, 36 2180-2188.en_US
dc.identifier.issn0887-6924
dc.identifier.urihttps://hdl.handle.net/11250/3030262
dc.description.abstractT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignant leukemia with extremely limited treatment for relapsed patients. N6‐methyladenosine (m6A) reader insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) participates in the initiation and growth of cancers by communicating with various targets. Here, we found IGF2BP2 was highly expressed in T-ALL. Gain and loss of IGF2BP2 demonstrated IGF2BP2 was essential for T-ALL cell proliferation in vitro and loss of IGF2BP2 prolonged animal survival in a human T-ALL xenograft model. Mechanistically, IGF2BP2 directly bound to T-ALL oncogene NOTCH1 via an m6A dependent manner. Furthermore, we identified a small-molecule IGF2BP2 inhibitor JX5 and treatment of T-ALL with JX5 showed similar functions as knockdown of IGF2BP2. These findings not only shed light on the role of IGF2BP2 in T-ALL, but also provide an alternative γ‑Secretase inhibitors (GSI) therapy to treat T-ALL.en_US
dc.description.abstractInhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemiaen_US
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleInhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemiaen_US
dc.title.alternativeInhibition of the m6A reader IGF2BP2 as a strategy against T-cell acute lymphoblastic leukemiaen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© The Author(s) 2022en_US
dc.source.pagenumber2180-2188en_US
dc.source.volume36en_US
dc.source.journalLeukemiaen_US
dc.identifier.doi10.1038/s41375-022-01651-9
dc.identifier.cristin2057035
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal